Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System

Author(s): Carmine Tomasetti, Chiara Montemitro, Annastasia L.C. Fiengo, Cristina Santone, Laura Orsolini, Alessandro Valchera, Alessandro Carano, Maurizio Pompili, Gianluca Serafini, Giampaolo Perna, Federica Vellante, Giovanni Martinotti, Massimo D. Giannantonio, Yong-Ku Kim, Marco D. Nicola, Antonello Bellomo, Antonio Ventriglio, Michele Fornaro, Domenico D. Berardis*.

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 4 , 2019

Become EABM
Become Reviewer

Abstract:

Depressive disorders represent protean psychiatric illnesses with heterogeneous clinical manifestations and a multitude of comorbidities leading to severe disability. In spite of decades of research on the pathophysiogenesis of these disorders, the wide variety of pharmacotherapies currently used to treat them is based on the modulation of monoamines, whose alteration has been considered the neurobiological foundation of depression, and consequently of its treatment. However, approximately one third to a half of patients respond partially or become refractory to monoamine-based therapies, thereby jeopardizing the therapeutic effectiveness in the real world of clinical practice. Recent scientific evidence has been pointing out the essential role of other biological systems beyond monoamines in the pathophysiology of depressive disorders, in particular, the glutamatergic neurotransmission. In the present review, we will discuss the most advanced knowledge on the involvement of glutamatergic system in the molecular mechanisms at the basis of depression pathophysiology, as well as the glutamate-based therapeutic strategies currently suggested to optimize depression treatment (e.g., ketamine). Finally, we will mention further “neurobiological targeted” approaches, based on glutamate system, with the purpose of promoting new avenues of investigation aiming at developing interventions that overstep the monoaminergic boundaries to improve depressive disorders therapy.

Keywords: Depressive disorders, glutamate, postsynaptic density, antipsychotics, antidepressants, NMDA, ketamine, mGluR.

[1]
World Health Organization. Depression and other common mental disorders. WHO 2017.
[2]
Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med 2013; 10: e1001547.
[3]
Culpepper L, Muskin PR, Stahl SM. Major depressive disorder: understanding the significance of residual symptoms and balancing efficacy with tolerability. Am J Med 2015; 128: 1-15.
[4]
Trevino K, McClintock SM, McDonald Fischer N, et al. Defining treatment-resistant depression: A comprehensive review of the literature. Ann Clin Psychiatry 2014; 26: 222-32.
[5]
Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-Term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry 2006; 163: 1905-17.
[6]
McIntyre RS, Filteau M-J, Martin L, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord 2014; 156: 1-7.
[7]
Carvalho AF, Berk M, Hyphantis TN, et al. The integrative management of treatment-resistant depression: A comprehensive review and perspectives. Psychother Psychosom 2014; 83: 70-88.
[8]
Rosenblat JD, McIntyre RS, Alves GS, et al. Beyond monoamines - novel targets for treatment-resistant depression: A comprehensive review. Curr Neuropharmacol 2015; 13: 636-55.
[9]
Martinotti G, Pettorruso M, De Berardis D, et al. Agomelatine increases BDNF serum levels in depressed patients in correlation with the improvement of depressive symptoms. Int J Neuropsychopharmacol 2016; 19: pyw003.
[10]
Castrén E, Voikar V, Rantamaki T. Role of neurotrophic factors in depression. Curr Opin Pharmacol 2007; 7: 18-21.
[11]
Tomasetti C, Iasevoli F, Buonaguro E, et al. Treating the synapse in major psychiatric disorders: the role of postsynaptic density network in dopamine-glutamate interplay and psychopharmacologic drugs molecular actions. Int J Mol Sci 2017; 18: 135.
[12]
Han KM, De Berardis D, Fornaro M, et al. Differentiating between bipolar and unipolar depression in functional and structural MRI studies Prog Neuropsychopharmacol Biol Psychiatry 2018; S0278- 5846; 30051-4
[13]
Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351-4.
[14]
Zarate CA, Singh JB, Carlson PJ, et al. A Randomized trial of an N-methyl-D-aspartate Antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856.
[15]
Berardis D De, Fornaro M, Valchera A, et al. Eradicating suicide at its roots: preclinical bases and clinical evidence of the efficacy of ketamine in the treatment of suicidal behaviors. Int J Mol Sci 2018; 19: E2888.
[16]
Jaso BA, Niciu MJ, Iadarola ND, et al. Therapeutic modulation of glutamate receptors in major depressive disorder. Curr Neuropharmacol 2017; 15: 57-70.
[17]
Moskal JR. Glutamatergic-basedrapid acting antidepressants: The link to synaptic plasticity. Curr Neuropharmacol 2017; 15: 2.
[18]
Kroes RA, Nilsson CL. Towards the molecular foundations of glutamatergic-targeted anti- depressants. Curr Neuropharmacol 2017; 15: 35-46.
[19]
Liu R-J, Aghajanian GK. Stress blunts serotonin- and hypocretin-evoked EPSCs in prefrontal cortex: Role of corticosterone-mediated apical dendritic atrophy. Proc Natl Acad Sci 2008; 105: 359-64.
[20]
Savitz J, Drevets WC. Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neurosci Biobehav Rev 2009; 33: 699-771.
[21]
Kang HJ, Voleti B, Hajszan T, et al. Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nat Med 2012; 18: 1413-7.
[22]
MacQueen GM, Yucel K, Taylor VH, et al. Posterior hippocampal volumes are associated with remission rates in patients with major depressive disorder. Biol Psychiatry 2008; 64: 880-3.
[23]
Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science 2012; 338: 68-72.
[24]
Boutouja F, Stiehm C, Platta H, et al. mTOR: A cellular regulator interface in health and disease. Cells 2019; 8: 18.
[25]
Fingar DC, Blenis J. Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004; 23: 3151-71.
[26]
Duman RS, Aghajanian GK, Sanacora G, et al. Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants. Nat Med 2016; 22: 238-49.
[27]
Jernigan CS, Goswami DB, Austin MC, et al. The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1774-9.
[28]
Karege F, Perroud N, Burkhardt S, et al. Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3β in ventral prefrontal cortex of depressed suicide victims. Biol Psychiatry 2007; 61: 240-5.
[29]
Ota KT, Liu R-J, Voleti B, et al. REDD1 is essential for stress-induced synaptic loss and depressive behavior. Nat Med 2014; 20: 531-5.
[30]
Kraus AC, Castr E, Kasper S, et al. Serotonin and Neuroplasticity - links between molecular, functional and structural pathophysiology in depression. Neurosci Biobehav Rev 2017; 77: 317-26.
[31]
Tokarski K, Bobula B, Wabno J, et al. Repeated administration of imipramine attenuates glutamatergic transmission in rat frontal cortex. Neuroscience 2008; 153: 789-95.
[32]
Bobula B, Tokarski K, Hess G. (2003) Repeated administration of antidepressants decreases field potentials in rat frontal cortex. Neuroscience 2003; 120: 765-9.
[33]
Bonanno G, Giambelli R, Raiteri L, et al. Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci 2005; 25: 3270-9.
[34]
Musazzi L, Milanese M, Farisello P, et al. Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: the dampening action of antidepressants. PLoS One 2010; 5: e8566.
[35]
Maya Vetencourt JF, Sale A, Viegi A, et al. The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science 2008; 320: 385-8.
[36]
Maffioletti E, Salvi A, Martin IC, et al. Study of the in vitro modulation exerted by the antidepressant drug escitalopram on the expression of candidate microRNAs and their target genes. Mol Cell Neurosci 2017; 85: 220-5.
[37]
Boku S, Nakagawa S, Toda H, et al. Neural basis of major depressive disorder: Beyond monoamine hypothesis. Psychiatry Clin Neurosci 2018; 72: 3-12.
[38]
Orsolini L, Tomasetti C, Valchera A, et al. New advances in the treatment of generalized anxiety disorder : The multimodal antidepressant Vortioxetine. Expert Rev Neurother 2016; 16: 483-95.
[39]
Moryl E, Danysz W, Quack G. Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol 1993; 72: 394-7.
[40]
Bonnet U. How much alcohol is in ketamine’s antidepressant action? Life Sci 2017; 168: 54-7.
[41]
Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351-4.
[42]
Scheidegger M, Walter M, Lehmann M, et al. Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action. PLoS One 2012; 7: e44799.
[43]
Wang L, Xia M, Li K, et al. The effects of antidepressant treatment on resting-state functional brain networks in patients with major depressive disorder. Hum Brain Mapp 2015; 36: 768-78.
[44]
Nugent AC, Robinson SE, Coppola R, et al. Preliminary differences in resting state MEG functional connectivity pre- and post-ketamine in major depressive disorder. Psychiatry Res Neuroimaging 2016; 254: 56-66.
[45]
Evans JW, Szczepanik J, Brutsché N, et al. Default mode connectivity in major depressive disorder measured up to 10 days after ketamine administration. Biol Psychiatry 2018; 84: 582-90.
[46]
Andrade C. Ketamine for depression, 3: does chirality matter? J Clin Psychiatry 2017; 78: e674-7.
[47]
Iasevoli F, Buonaguro EF, Sarappa C, et al. Regulation of postsynaptic plasticity genes’ expression and topography by sustained dopamine perturbation and modulation by acute memantine: Relevance to schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2014; 54: 299-314.
[48]
Zarate CAJ, Singh JB, Quiroz JA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006; 163: 153-5.
[49]
Nguyen L, Scandinaro AL, Matsumoto RR. Deuterated (d6)-dextromethorphan elicits antidepressant-like effects in mice. Pharmacol Biochem Behav 2017; 161: 30-7.
[50]
Murrough JW, Wade E, Sayed S, et al. Dextromethorphan/ quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial. J Affect Disord 2017; 218: 277-83.
[51]
Ebada ME. Drug repurposing may generate novel approaches to treating depression. J Pharm Pharmacol 2017; 69: 1428-36.
[52]
Henter ID, de Sousa RT, Zarate CAJ. Glutamatergic modulators in depression. Harv Rev Psychiatry 2018; 26: 307-19.
[53]
Miyamoto Y, Iegaki N, Fu K, et al. Striatal N-Acetylaspartate Synthetase Shati/Nat8l regulates depression-like behaviors via mGluR3-mediated serotonergic suppression in mice. Int J Neuropsychopharmacol 2017; 20: 1027-35.
[54]
Wang CC, Kuo JR, Huang SK, et al. Metabotropic glutamate 7 receptor agonist AMN082 inhibits glutamate release in rat cerebral cortex nerve terminal. Eur J Pharmacol 2018; 823: 11-8.
[55]
Quiroz JA, Tamburri P, Deptula D, et al. Efficacy and safety of basimglurant as adjunctive therapy for major depression. JAMA Psychiatry 2016; 73: 675.
[56]
Huang Y, Lane H, Lin C. New treatment strategies of depression: based on mechanisms related to neuroplasticity. Neural Plast 2017; 4605971.
[57]
Wilkinson ST, Kiselycznyk C, Banasr M, et al. Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression. J Affect Disord 2018; 241: 514-8.
[58]
Milev RV, Giacobbe P, Kennedy SH, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 4. Neurostimulation Treatments. Can J Psychiatry 2016; 61: 561-75.
[59]
Rakesh G, Pae C, Masand PS, et al. Beyond serotonin: newer antidepressants in the future. Expert Rev Neurother 2017; 1: 1-14.
[60]
Pfleiderer B, Michael N, Erfurth A, et al. Effective electroconvulsive therapy reverses glutamate/glutamine deficit in the left anterior cingulum of unipolar depressed patients. Psychiatry Res 2003; 122: 185-92.
[61]
Michael N, Erfurth A, Ohrmann P, et al. Metabolic changes within the left dorsolateral prefrontal cortex occurring with electroconvulsive therapy in patients with treatment resistant unipolar depression. Psychol Med 2003; 33: 1277-84.
[62]
George MS, Nahas Z, Kozel FA, et al. Mechanisms and state of the art of transcranial magnetic stimulation. J ECT 2002; 18: 170-81.
[63]
Fitzgerald PB, McQueen S, Herring S, et al. A study of the effectiveness of high-frequency left prefrontal cortex transcranial magnetic stimulation in major depression in patients who have not responded to right-sided stimulation. Psychiatry Res 2009; 169: 12-5.
[64]
Cho SS, Strafella AP. rTMS of the left dorsolateral prefrontal cortex modulates dopamine release in the ipsilateral anterior cingulate cortex and orbitofrontal cortex. PLoS One 2009; 4: e6725.
[65]
Siebner HR, Rothwell J. Transcranial magnetic stimulation: new insights into representational cortical plasticity. Exp Brain Res 2003; 148: 1-16.
[66]
Nichols DE. Psychedelics. Pharmacol Rev 2016; 68: 264-355.
[67]
Baumeister D, Barnes G, Giaroli G, et al. Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles. Ther Adv Psychopharmacol 2014; 4: 156-69.
[68]
Garcia-romeu A, Kersgaard B, Addy PH, et al. Clinical applications of hallucinogens: A review. Exp Clin Psychopharmacol 2016; 24: 229-68.
[69]
Lyons T, Carhart-Harris RL. More realistic forecasting of future life events after psilocybin for Treatment-resistant depression. Front Psychol 2018; 9: 1721.
[70]
Halberstadt AL. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behav Brain Res 2015; 15: 99-120.
[71]
Carhart-Harris RL. Serotonin, psychedelics and psychiatry. World Psychiatry 2018; 17: 358-9.
[72]
Serafini G, Adavastro G, Canepa G, et al. The Efficacy of buprenorphine in Major Depression, Treatment-Resistant Depression and suicidal behavior: A systematic review. Int J Mol Sci 2018; 15: 19.
[73]
Fornaro M, Kardash L, Novello S, et al. Progress in bipolar disorder drug design toward the development of novel therapeutic targets: A clinician’s perspective. Expert Opin Drug Discov 2018; 13: 221-8.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 25
ISSUE: 4
Year: 2019
Page: [381 - 387]
Pages: 7
DOI: 10.2174/1381612825666190312102444
Price: $65

Article Metrics

PDF: 51
HTML: 7